| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35860eb7222eea6903712bd63ad3dad7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2813242b6ebe184beb6ff9442207344a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af804260b06389290099e5e59449b139 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24162 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N63-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04 |
| filingDate |
2004-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e33f75f01f21a4012438661eb87e91c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f32e965d3993404e73f573ecaece344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fb938768fde6c166a33b5bfda4728c3 |
| publicationDate |
2007-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007036758-A1 |
| titleOfInvention |
Mutants of vaccinia virus as oncolytic agents |
| abstract |
The present invention relates to mutant oncolytic vaccinia viruses and their use for selective destruction of cancer cells. The mutant vaccinia viruses of the invention include those having a reduced ability to inhibit the antiviral dsR-NA dependent protein kinase (PKR) and increased sensitivity to interferon. Such mutants include, for example, vaccinia viruses having mutations in the E3L and/or K3L regions. The invention is based on the discovery that vaccinia viruses having mutations in the E3L region are capable of replication in oncogenic cells resulting in cell lysis. The invention further provides methods for treating proliferative disorders, such as neoplasms, in a host comprising administration of mutant vaccinia virus under conditions which result in substantial lysis of the proliferating cancer cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10765711-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426460-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11285209-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017205674-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458203-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10639366-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11541087-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253560-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10512662-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10842835-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10548930-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10736962-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11242509-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019183947-A1 |
| priorityDate |
2003-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |